The solid Amos particle is composed of two or three active ingredients selected from the long-term muscle antagonists (lamas),One b832222 long acting agonist (Laba) and one inhaled corticosteroid (ICS),together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least -50 ° C. Claim 7: The particles of one, any of the preceding claims, characterized in that the co-solid is a sugar and / or a sugar derivative. Claim 9: The particles of any of the preceding claims, characterized in that the co-solid is selected from dextrose, fructose, glucosamine, glucose, lactose, mannitol, maltitol, mannose, sorbitol, sucrose, trehalose, xylitol and combinations thereof. Claim 14: The particles of any one of the preceding claims,Marked as selected when the Lama appears. Laboratories selected from thiotropio, aclidinio, glicoloroni, oxibutinina and darifenocina will be selected from formaldehyde, salmeterol, nitterol, carmoterol and ICs in their presence. Claim 15: the particles in any of the above requirements are characterized in that they contain: oxybutynin and formaldehyde； darifanine and formaldehyde； oxybutylamine, thyroxine and beclomethasone； darifanin, thyroxine and beclomethasone； oxybutylamine and salmeterol； darifanina and salmeterol； oxybutylamine,Salmeterol and fluticasone； darienate, salmeterol and fluticasone； glycerine, ammonium chloride and nitrate； glycerin and formaldehyde； thiotropio and formaldehyde； thiotropio and olodatro； thiotropio and indacatro； or budisonida and formaldehyde. 19. Claim 16: the process of preparing a solid powder according to any of the above requirements, characterized by dilution or spray drying of the aqueous solution of the active ingredient with an acceptable co solid solution on the drug.Partículas amorfas sólidas que comprenden una íntima de dos o tres ingredientes activos seleccionados de un antagonista muscarínico de acción prolongada (LAMA), un b₂-agonista de acción prolongada (LABA) y un cort
